Peptidic SN-38 Micelles for Brain Tumor Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing delivery systems for SN-38, a potent anticancer drug, face challenges due to its insolubility in water at acidic pH, leading to ineffective administration and limited bioavailability, particularly in brain tumors with intact blood-brain barriers.
Innovation Solution
The formation of micelles through spontaneous self-assembly of peptide conjugates of SN-38 in an aqueous medium, which significantly increases the apparent solubility of SN-38 lactone in water and allows it to cross the blood-brain barrier, delivering therapeutic concentrations of SN-38 to the brain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SN-38 is administered in its lactone form to maintain anticancer activity, then therapeutic efficacy is improved, but water solubility deteriorates making administration infeasible
Solution Approach 1:
The patent uses peptide conjugates as intermediary carriers that temporarily bind to SN-38 lactone, enabling it to dissolve in water at acidic pH. The peptide-SN-38 conjugate acts as a mediator between the lipophilic drug and aqueous environment, resolving the solubility contradiction while preserving the active lactone form.
Solution Approach 2:
The patent changes the chemical parameters of SN-38 by conjugating it with peptide sequences that alter its solubility properties. The conjugate modifies the drug's physical-chemical characteristics to enable water solubility at acidic pH without changing the core lactone structure responsible for anticancer activity.
2Quantity of substance
If SN-38 is solubilized using basic pH solutions like NaOH, then water solubility is improved, but the lactone ring opens converting to inactive carboxylate form
Solution Approach 1:
The patent changes the pH parameter of the delivery system to acidic conditions (pH 3-5), which is the opposite of conventional basic pH solubilization. This acidic parameter change simultaneously achieves water solubility through peptide conjugation and maintains the lactone ring closed, preserving anticancer activity.
3Quantity of substance
If peptide conjugates are used to improve water solubility at acidic pH, then solubility is improved, but the ability to cross the blood-brain barrier deteriorates
Solution Approach 1:
The patent segments the delivery system into distinct functional components: a hydrophilic peptide segment for water solubility and a lipophilic SN-38 segment for membrane penetration. This segmentation allows each component to perform its specialized function, with the conjugate as a whole achieving both solubility and BBB penetration.
Solution Approach 2:
The patent applies local quality by designing the peptide conjugate with specific local properties: the peptide portion provides water solubility at acidic pH, while the SN-38 portion maintains lipophilic character for membrane interaction. This local differentiation of properties enables the conjugate to achieve contradictory functions simultaneously.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The micelles achieve a solubility increase of at least 500 times for SN-38 lactone, enabling effective treatment of brain tumors by overcoming the limitations of existing delivery systems and achieving therapeutic activity in brain and cerebrospinal fluid.
Implementation Method 1
The formation of micelles through spontaneous self-assembly of peptide conjugates of SN-38 in an aqueous medium
Implementation Method 2
allows it to cross the blood-brain barrier, delivering therapeutic concentrations of SN-38 to the brain
Data Source
AI summary
Micelles of peptidic conjugates of SN-38 loaded with one or more free therapeutic active agents which anticancer activity, such as free SN-38 lactone, process for their preparation, pharmaceutical compositions comprising them, and their therapeutical indications as anticancer drugs.